Literature DB >> 1343079

Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura.

F Mollica1, S Li Volti, R Garozzo, G Russo.   

Abstract

A prospective study was performed to verify whether early administration of prednisone could be useful in preventing the development of nephropathy in anaphylactoid purpura. Only patients without signs of nephropathy upon initial presentation entered into the study. A total of 84 patients received delta-prednisone (1 mg/kg per day per os for 2 weeks), and 84 patients did not receive steroids. The patients were followed for 24-36 months. None of the 84 patients treated with steroids and 10 (11.9%) of the 84 control patients developed nephropathy 2-6 weeks after the acute episode. In 2 other patients of the untreated group, signs of renal involvement appeared 2 and 6 years after the acute episode respectively. The difference in the prevalence of nephropathy between the two groups is highly significant (P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1343079     DOI: 10.1007/bf01958961

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Prophylaxis and therapy of glomerulonephritis in the course of anaphylactoid purpura. The results of a polycentric clinical trial.

Authors:  L Peratoner; F Longo; L Lepore; P Freschi
Journal:  Acta Paediatr Scand       Date:  1990-10

2.  IgA immune complexes in Henoch-Schönlein purpura.

Authors:  R J Levinsky; T M Barratt
Journal:  Lancet       Date:  1979-11-24       Impact factor: 79.321

3.  Similar disturbances in B cell activity and regulatory T cell function in Henoch-Schönlein purpura and systemic lupus erythematosus.

Authors:  M G Beale; G S Nash; M J Bertovich; R P MacDermott
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

4.  Mechanism of action of glucocorticosteroids. Inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4.

Authors:  J S Goodwin; D Atluru; S Sierakowski; E A Lianos
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

5.  Circulating IgA-immune complexes in Henoch-Schönlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA.

Authors:  R H Kauffmann; W A Herrmann; C J Meÿer; M R Daha; L A Van Es
Journal:  Am J Med       Date:  1980-12       Impact factor: 4.965

6.  Incidence of renal complications in Schönlein-Henoch purpura syndrome in dependence of an early administration of steroids.

Authors:  J Buchanec; V Galanda; S Beláková; M Minárik; M Zibolen
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

7.  Henoch-Schönlein nephritis: long-term prognosis of unselected patients.

Authors:  O Koskimies; S Mir; J Rapola; J Vilska
Journal:  Arch Dis Child       Date:  1981-06       Impact factor: 3.791

8.  Circulating immune complexes containing IgA, IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schoenlein nephritis. Correlation with clinical and histologic signs of activity.

Authors:  R Coppo; B Basolo; G Martina; C Rollino; M De Marchi; F Giacchino; G Mazzucco; M Messina; G Piccoli
Journal:  Clin Nephrol       Date:  1982-11       Impact factor: 0.975

9.  IgA-containing circulating immune complexes in dermatitis herpetiformis, Henoch-Schönlein purpura, systemic lupus erythematosus and other diseases.

Authors:  R P Hall; T J Lawley; J A Heck; S I Katz
Journal:  Clin Exp Immunol       Date:  1980-06       Impact factor: 4.330

10.  Increase of IgA-bearing peripheral blood lymphocytes in children with Henoch-Schoenlein purpura.

Authors:  H Kuno-Sakai; H Sakai; Y Nomoto; I Takakura; M Kimura
Journal:  Pediatrics       Date:  1979-12       Impact factor: 7.124

View more
  30 in total

Review 1.  Henoch-Schönlein purpura.

Authors:  E J Tizard
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

2.  Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis.

Authors:  Salvatore Li Volti; Giovanni Li Volti
Journal:  Pediatr Nephrol       Date:  2003-09-12       Impact factor: 3.714

3.  Outcome of Henoch-Schönlein purpura 8 years after treatment with a placebo or prednisone at disease onset.

Authors:  Outi Jauhola; Jaana Ronkainen; Olli Koskimies; Marja Ala-Houhala; Pekka Arikoski; Tuula Hölttä; Timo Jahnukainen; Jukka Rajantie; Timo Örmälä; Matti Nuutinen
Journal:  Pediatr Nephrol       Date:  2012-02-05       Impact factor: 3.714

Review 4.  Gastrointestinal manifestations of Henoch-Schonlein Purpura.

Authors:  Ellen C Ebert
Journal:  Dig Dis Sci       Date:  2008-03-20       Impact factor: 3.199

Review 5.  Treatment-based literature of Henoch-Schönlein purpura nephritis in childhood.

Authors:  Marco Zaffanello; Vassilios Fanos
Journal:  Pediatr Nephrol       Date:  2008-12-09       Impact factor: 3.714

6.  Early prednisone treatment and nephropathy in anaphylactoid purpura.

Authors:  A F Temmel; W Emminger; B Schroth; H A Zaunschirm; H Gadner
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

7.  Anaphylactoid purpura and renal disease: the case against routine steroids.

Authors:  S Blazer; R Brik; M Berant
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

Review 8.  Clinical practice: Diagnosis and management of Henoch-Schönlein purpura.

Authors:  Hugh J McCarthy; E Jane Tizard
Journal:  Eur J Pediatr       Date:  2009-12-12       Impact factor: 3.183

9.  Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report.

Authors:  A A Nikibakhsh; H Mahmoodzadeh; M Karamyyar; S Hejazi; M Noroozi; A A Macooie; A Gholizadeh; L Gholizadeh
Journal:  Int J Rheumatol       Date:  2010-06-15

Review 10.  Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review.

Authors:  Pamela F Weiss; James A Feinstein; Xianqun Luan; Jon M Burnham; Chris Feudtner
Journal:  Pediatrics       Date:  2007-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.